Research platform
Drug-design engine
An internal AI platform for exploring molecules and biological interactions. Scientists use it to design and assess candidates across different targets and types of drug.
Explore Drug-design engineHealth / Models
Isomorphic Labs
Researched by DeployBriefLooking for new medicines on a computer.
Isomorphic Labs combines AI research with chemistry and biology to design potential medicines. It develops its own drug-design engine and works with pharmaceutical partners on discovery programmes.
The story behind the company.
Finding a useful drug means understanding how molecules behave and interact with biological targets. Isomorphic Labs uses AI models to help its scientists explore that space, shifting part of the early discovery work from the laboratory to the computer.
The company’s technology builds on work associated with AlphaFold and extends into a broader drug-design engine. Its researchers combine machine learning with medicinal chemistry and biology, rather than treating a computer prediction as a finished medicine.
Its work includes partnerships with pharmaceutical companies and an internal pipeline focused on oncology and immunology. These are drug-discovery programmes, not treatments available to patients. A promising molecule still needs experimental testing and the further development required of a medicine.
What they’re building.
Explore the products and platforms.
Research collaborations
Discovery partnerships
Joint discovery programmes with pharmaceutical partners. They combine Isomorphic Labs’ AI and drug-design work with a partner’s expertise in developing medicines.
Explore Discovery partnershipsResearch pipeline
Internal discovery programmes
The company’s own work on potential medicines, with a focus on oncology and immunology. These programmes are research and development, not approved therapies or a consumer product.
Explore Internal discovery programmesGet to know
Isomorphic Labs.
Go directly to the people building it.
Researched, not sponsored.
DeployBrief prepared this profile from linked official sources. The company has not submitted or approved it. Inclusion does not imply a purchase, partnership or endorsement. Logos belong to their respective owners.
Profile sources reviewed 4 October 2026.
A dated snapshot, not a live news feed.